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Abstract
Medication adherence has been defined as the process by which patients take their medications
on how they are prescribed (Ruppar et al., 2015). Medication nonadherence has become a critical
healthcare issue. Several interventions have been tried to increase adherence. Therefore, the
objective of this review is to assess if a structured educational program directed to providers and
staff could increase medication adherence among patients who are prescribed lipid-lowering
medications for primary and secondary prevention of cardiovascular disease. The gathered
evidence led to the development of a quality improvement project. Three databases were
screened to answer the clinical question, and six articles were included in the review. The
educational programs ranged from 90 minutes of training up to 2-day educational sessions. The
programs included scientific updates, clinical guidelines, feedback, and communication skills.
Five out of the six studies found a significant increase in medication adherence after the
intervention. Even when different approaches were used, it is feasible to create an educational
program targeting providers and their staff to increase lipid-lowering medication adherence.
A Quality Improvement (QI) project was implemented in a local Primary Care practice. The
project was designed as a pre-post intervention survey. The purpose of the QI was to increase the
skills and awareness of the provider's staff to increase the patient's adherence to lipid-lowering
medication. After the educational intervention, there was an improvement in staff knowledge,
awareness, and skills to assess, educate, and engage patients to promote patients' adherence to
lipid-lowering medication. More research is needed to prove the efficacy of different types of
intervention targeting providers over medication adherence in other chronic conditions.
Keywords: medication adherence, lipid-lowering medication, providers, educational
intervention
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Introduction
Background
Hypercholesterolemia has been recognized as a significant risk factor for cardiovascular
disease. Total serum cholesterol below the 200 mg/dl is considered one of the critical elements of
good cardiovascular health. However, more than 28 million adults in the United States have
serum cholesterol over 240 mg/dl (Benjamin et al., 2019). The United State Preventive Services
Task Force (USPSTF) recommends that adults with more than one risk of developing
cardiovascular disease (CVD) from 40 to 76 years old, and with a greater than 10 % in the 10year risk assessment of cardiovascular events should be on statins for primary prevention
(USPSTF, 2016). Moreover, the American College of Cardiology (ACC) recommends the use of
high-intensity statins therapy for secondary prevention on patient younger than 76 years old that
have a clinical CVD (Grundy et al., 2019).
Statins and other lipid-lowering medications have been commonly used for both primary
and secondary prevention, yet, patient's nonadherence usually deters the role of statins.
Nonadherence to medicine is a prevalent issue with a diverse range of negative consequences.
Between 30% to 50% of patients with chronic conditions such as diabetes and hypertension do
not take the medications as prescribed. Studies have demonstrated that after the first year of
treatment, about half of the patients stop using them, and it is estimated that by the second year,
only 25 % of the patients continue been adherent (Rash, Campbell, Tonelli, & Campbell, 2016).
In the United States, medication nonadherence is considered a significant public healthcare
problem. About half of the patients with chronic diseases are nonadherent, and it is estimated
that more than $100 billion are spent on issues associated with poor medication adherence (Kini
& Ho, 2018).
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Medication adherence is a complex process that involves elements from both the patients
and the providers (Kini & Ho, 2018). Several factors have been associated with statins and other
lipid-lowering medication discontinuation, for instance, low socioeconomic status and high
copayments. Likewise, factors such as side effects, low self-efficacy, statins used for primary
prevention, or depression, increase the rate of withdrawal (Rash, Campbell, Tonelli, & Campbell,
2016). Patient's self-care characteristics, beliefs, socioeconomic status, or health literacy are
associated with the patient's discontinuation of treatment (Rash, Campbell, Tonelli, & Campbell,
2016). Additionally, complex prescription regimes, inappropriate follow up, inadequate patientprovider relationships, weak communication, and lack of patient-centered care can also deter the
adherence process (Hickson et al., 2017).
Different approaches to assess medication adherence includes self-report, pharmacy
claims for refills, and electronic drug monitors (Kini & Ho, 2018). In some instances, serum
levels of cholesterol, triglycerides, and low-density lipoproteins (LDL) could be a good indicator
of medication adherence (Deichmann et al., 2016). However, one prevalent issue is the lack of a
standard tool to measure nonadherence and lack of consistent interventions (Van Driel et al.,
2016). Several initiatives have been proposed to increase patient adherence. For instance,
improvement of patient/provider relationship, follow up guidelines, generating clinical pathways
to guarantee appropriate decision-making, strengthening of healthcare delivery, adequate followup, simplification of medical regimen, and the use of technology (Lee et al., 2016).
Even when different interventions have been implemented, only complex interventions
that included active provider involvement and close patient follow up demonstrated significant
improvement (Van Driel et al., 2016). Moreover, a study designed to evaluate the effect of
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financial incentives on lipid levels shown that only when physicians and patients shared
incentives, a significative reduction on the lipid levels was achieved (Asch et al., 2015).
Rationale
Primary care providers play an essential role in the assessment, management, and
treatment of hyperlipidemia for primary and secondary prevention of cardiovascular disease.
Proper communication between providers and patients can have a positive influence on patients'
adherence to different medication regimens, especially when managing chronic conditions. The
likelihoods of poor medication adherence are significantly higher when patient-provider
communication lacked focus on the discussion about medication, patients' preferences, and
patients' psychosocial characteristics (Schoenthaler, Knafl, Fiscella, & Ogedegbe, 2017).
Provider-patient communication is considered an essential reason why a vast number of
patients become nonadherent (Brinton, 2018). The Understanding Statin Use in America and
Gaps in Education (USAGE) survey exposed how poor communication leads to a lack of
patients' understanding of the benefits of statin use, becoming a crucial factor in patient's
discontinuation of treatment (Brinton, 2018). Interventions at the patient, provider, and health
system levels tend to have a positive effect on the management of cardiovascular events. Hence
medication adherence becomes an essential issue when considering primary or secondary
prevention.
Several studies agree that providers should assess adherence in every encounter and that
lack of patient-provider communication is a negative factor in the process of adherence (Ruppar
et al., 2015). Nevertheless, the lack of consensus on how to address nonadherence and the
absence of a definite clinical guideline could affect the effectiveness of the provider's role. Some
studies suggest different strategies to approach this subject. In some instances, educational and
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behavioral approaches have been successful. Besides, other studies provide recommendations to
improve patient-provider communication, not only addressing the patient but also the providers.
However, there is not a single algorithm that could aid providers to discuss nonadherence topics
(Ruppar et al., 2015).
Nevertheless, the collaboration between patients and providers toward a common goal is
more effective than individuals' efforts. Providers play a crucial role in shaping patients' attitudes
and beliefs regarding self-efficacy, medication adherence, and chronic disease management.
Lack of practitioners focus on adherence issues at the time of prescribing, and their positions
regarding statin therapy and nonadherence management are known to affect patients' adherence
negatively (Barfoed et al.,2016).
Prior systematic reviews have shown that quality improvement projects can be useful to
manage chronic conditions and to improve medication adherence in patients with cardiovascular
events (Lee et al., 2016). Changes at the patient/provider relationship include abiding by the
guidelines or creating clinical pathways to ensure appropriate decision-making, intensification of
healthcare delivery, proper follow-up, simplification of medical regimen, and use of technology
(Lee et al., 2016).
Objective
The purpose of this review is to assess if a structured educational program directed to
providers and the staff could increase medication adherence among patients who are prescribed
lipid-lowering medications for primary and secondary prevention of cardiovascular disease. The
objective of the systematic review is to gather evidence for the development of a quality
improvement project (QI). The goal is to increase patients' adherence to lipid-lowering
medication through a structured intervention targeting primary care providers and their staff as
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well as identify tools and guidelines that could be implemented in the primary care setting to
improve patient adherence.
Methodology
Information sources
After formulating the clinical question and determined the PICO concepts, a preliminary
literature review was performed. Three different electronic databases were screened: Medline
ProQuest, Embase, and the Cumulative Index of Nursing and Allied Health Literature
(CINAHL). Embase produced a higher number of articles; however, most of the reports did not
include some elements of the clinical question. Hence, Medline ProQuest was the primary
database regarding the number of useful articles after the initial screening with the features of the
PICO question.
Search strategy
The screening process used the concepts of "medication adherence," "lipid-lowering
medication," and providers to answer the elements of the clinical question. Other terms were
included, such as "medication compliance," "drug adherence," "medication nonadherence," or
noncompliance, statins, physicians, "general practitioners," "advanced practice nurses," and
"nurse practitioners." The use of Boolean operators, MeSH terms, CINAHL headings, and
Emtrees were included in the research phrases to identify the studies addressing the impact of an
intervention on medical providers on lipid-lowering medication adherence.
Each database was screened using the keywords and the specific Boolean operators to
increase the possible items to be considered. In Medline ProQuest, MeSH terms were added to
the research keywords as follow:
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Medline ProQuest: (Adher* or complian* or comply or noncomplian* or nonadher* or
MESH.EXACT("Medication Adherence") or MESH.EXACT("Patient Compliance")) AND
(MESH.EXACT("Hydroxymethylglutaryl-CoA Reductase Inhibitors") or
MESH.EXACT("Rosuvastatin Calcium") or MESH.EXACT("Atorvastatin") or
MESH.EXACT("Simvastatin") OR MESH.EXACT("Ezetimibe, Simvastatin Drug
Combination") or “lipid-lowering medication*” or “lipid-lowering drug*” or statin* or Crestor or
Lipitor or simvastatin) AND (MESH.EXACT("General Practitioners") OR
MESH.EXACT("Family Nurse Practitioners") or MESH.EXACT("Health Personnel") or
MESH.EXACT("Nurse Practitioners") or MESH.EXACT("Nurses") or
MESH.EXACT("Medical Staff") or provider* or “general practitioner*” or physician* or nurse*
or doctor* or “medical staf*”).
The CINAHL database was screened adding the CINAHL headings to the keywords as
follows: ((MH "Medication Compliance") OR (MH "Patient Compliance") or Adher* or
complian* or comply or noncomplian* or nonadher* ) AND ((MH "Antilipemic Agents") or
(MH "Statins") OR (MH "Atorvastatin") OR (MH "Rosuvastatin") OR (MH "Simvastatin") or
"lipid-lowering medication*" or "lipid-lowering drug*" or statin* or crestor or Lipitor or
simvastatin) AND ((MH "Advanced Practice Nurses") OR (MH "Nurse Practitioners") OR (MH
"Adult Nurse Practitioners") OR (MH "Family Nurse Practitioners") OR (MH "Gerontologic
Nurse Practitioners") or (MH "Physicians, Family") or provider* or "general practitioner*" or
physician* or nurse* or doctor* or "medical staf*").
Lastly, Embase’s Emtrees term were included this way: ('medication compliance'/de OR
adher* OR complian* OR comply OR noncomplian* OR nonadher*) AND
('hydroxymethylglutaryl coenzyme a reductase inhibitor'/de OR 'antilipemic agent'/de OR
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'rosuvastatin'/de OR 'atorvastatin'/de OR 'simvastatin'/de OR 'lipid-lowering medication*' OR
'lipid-lowering drug*' OR statin* OR crestor OR lipitor OR simvastatin) AND ('general
practitioner'/de OR 'nurse'/de OR 'nurse practitioner'/de OR 'pharmacist'/de OR 'physician'/de OR
'medical staff'/de OR provider* OR 'general practitioner*' OR physician* OR nurse* OR doctor*
OR cardiologist* OR pharmacist* OR 'medical staf*').
The initial search comprised journal articles and systematic reviews from 1989 to 2019.
Then inclusion and exclusion criteria were applied to find full-text articles, peer-reviewed, and
published only in English between January 2014 and September 2019. The reports retrieved were
exported to RefWorks as a database management tool. Depending on the relevance, according to
the PICO question, the articles were assigned to three different folders. After eliminating
duplicates articles, an exhaustive analysis of titles and abstracts was performed. A total of 339
articles were excluded because they did not address the elements of the PICO question and were
included in the irrelevant to the PICO question folder.
Eligibility criteria
Only those articles written in English, published in peer review journals in the past five
years (January 2014-December 2019), were included. Those articles with interventions directed
to clinical providers and measuring the effect on a statin or other lipid-lowering medication
adherence were included. All the pieces were screened, and those that did not include an
intervention addressing clinical providers were excluded. The primary outcome was to assess the
effect of educational intervention on providers over the adherence to lipid-lowering medication.
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Results
Study selection
After the initial search, a total of 2568 items were retrieved. Out of that total, 1228 articles were
found on Embase, 353 in CINAHL, and 987 in Medline ProQuest. After applying selection
criteria such as full-text articles, peer-reviewed, and published in English only between January
2014 and September 2019, a total of 413 articles were identified. Out of that total, 29 pieces were
eliminated because of duplication. The 384 articles were screened by a thorough analysis of the
abstract, methodology, and interventions leading to exclude 339 because they did not address the
elements of the PICO question. The rest of the articles' abstracts were thoroughly reviewed.
Those that did not include interventions involving providers were excluded. The full text of the
articles was then analyzed, and only six items met the inclusion criteria (see Figure 1 for the
PRISMA flow chart).
Data collection process and data items
For the data collection, a chart was created to include information regarding
methodology, participants, type of interventions, and outcomes. Each article was analyzed to
gather data such as type of study, sample, type of intervention, randomization, outcomes, results,
discussion, limitations, relevance, and risk of bias. The risk of bias was assessed on methodology
design, randomization, blinding, and report of findings as recommended by the Cochrane tool to
assess the risk of bias in systematic reviews.
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Figure 1: PRISMA Flow Diagram
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Study characteristics
Only two studies were carried on in the United States (USA), another one in Argentina
and the other three in Europe (one in the United Kingdom (UK) and two in Italy). A total of
16,243 patients were included in the studies, as well as about 835 providers that included general
practitioners, nurses, nurse practitioners, and office staff. Out of the six studies, two are
randomized control trials (RCT) and four quasi-experimental.
All the studies included an intervention with clinical providers and staff. All the
interventions involved a tailored educational session performed by a pharmacist or more
specialized professionals with the focus on updated cholesterol management guidelines,
assessment and management of hypercholesterolemia, feedback, and communication skills.
Educational intervention ranges from a 90 minutes session (Olomu, Hart-Davidson, Luo, KellyBlake, & Holmes-Rovner, 2016; Olomu et al., 2016) up to a 2-day intensive training (Gulayin et
al. (2019), or coached pharmacist-led interventions (Lowrie, Lloyd, McConnachie, & Morrison,
2014). One study also included outreach visits and the incorporation of a smartphone decision
making application (Gulayin et al. (2019). In the studies carried on in the USA, patients were
also trained in communication skills. The focus of the intervention relied on the patient-centered
care model. The follow-up visits included the use of a checklist tool that improved patient
engagement and decision making (Olomu, Hart-Davidson, Luo, Kelly-Blake, & Holmes-Rovner,
2016; Olomu et al., 2016).
Patients in the study were adults older than 18 years old, except for the research
performed by Gulayin et al. (2019) that included patients between 40-74 years. Four of the
studies included patients with a confirmed history of cardiovascular disease, diabetes mellitus,
and hypercholesterolemia, or high risk of developing cardiovascular disease (Gulayin et al.,
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2019; Lowrie, Lloyd, McConnachie, & Morrison, 2014; Olomu, Hart-Davidson, Luo, KellyBlake, & Holmes-Rovner, 2016; Olomu et al., 2016). Meanwhile, the other two studies included
patients receiving statin prescription regardless of whether they were for primary or secondary
prevention (Arcoraci et al., 2014; Casula et al., 2016).
Adherence was measured differently in the studies. Two studies assessed adherence by
using the medication possession ratio (MPR) (Arcoraci et al., 2014; Casula et al., 2016). Another
one used a self-reporting tool, the Morisky-Green questionnaire (Gulayin et al.,2019). The other
two used patients self-reporting (Olomu, Hart-Davidson, Luo, Kelly-Blake, & Holmes-Rovner,
2016; Olomu et al., 2016) and the last one measured level of cholesterol and LDL (Lowrie,
Lloyd, McConnachie, & Morrison, 2014).
In four of the studies, the interventions led to a significant increase in medication
adherence (Arcoraci et al., 2014; Casula et al., 2016; Olomu, Hart-Davidson, Luo, Kelly-Blake,
& Holmes-Rovner, 2016; Olomu et al., 2016). They also found a significant improvement in
serum cholesterol levels, which was directly related to the enhancement in adherence — overall,
the percentage of patients who received the correct dose of statin increased. Two of the studies
also focus on the engagement of patients in the decision-making process. The improvement in
the communication between providers and patients resulted in a significative increase of
adherence (Olomu, Hart-Davidson, Luo, Kelly-Blake, & Holmes-Rovner, 2016; Olomu et al.,
2016).
Results from individual studies
The study by Casula et al. (2016) aimed to assess how effective an educational program
addressed to providers could be on improving statin therapy adherence. They prepared an
intervention that included a document focused on a scientific update on dyslipidemia—diagnosis,
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monitoring, drug utilization, healthy lifestyle modification, and how to improve adherence and
persistence to treatment. They also facilitated information about accumulated statistics on statin
use and adherence benchmarked to other providers in the area.
The study was designed as pre-post interventional quasi-experimental research. It
included a total of 705 general practitioners in the region of Lombardy (Italy) that have patients
on lipid-lowering medications and their 10,621 patients. The variables considered were
adherence and persistence. In this study, adherence was measured by calculating the medication
possession ratio (MPR). It was calculated by dividing the number of drug coverage' days by the
number of days in the observation period. Persistence was assessed by determining the time
elapsed between prescriptions.
Most of their initial data were obtained from the pharmacy's database. They identified
two cohorts. One cohort received their first statin prescription before the intervention (PRE-i),
and the other had their first prescription after the intervention (POST-i); each patient was
followed up for one year. An analysis of adherence and persistence was conducted in both
cohorts and the results compared using Student t-test, 1-way ANOVA, or Mann-Whitney test
(Casula et al., 2016).
Most of the patients in both cohorts were male (51%) and between 40 to 79 years old.
The main finding demonstrated a significant increase in adherence in the POST-i group as well
as an increase in the number of prescriptions filled (persistence). According to Casula et al.
(2016), these results were relevant because only healthcare providers can modify their
prescriptive practice. Skilled and well-informed providers can have a positive influence on
patients' perceptions and trust, leading to stronger patient-provider relationships and
improvement on patients' adherence. However, the assessment of adherence was based on
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pharmacy data, which is not always accurate and should be complemented with other tools such
as serum cholesterol values. The strength of this study is the large sample included; however,
the authors did not consider the presence of other associated comorbidities or additional
therapeutic. Moreover, the lack of a control group makes it difficult to assess how effective the
intervention is concerning the usual care.
Similarly, Arcoraci et al. (2014) evaluated the effect of an educational program offered to
general practitioners on the patient's adherence to lipid-lowering medication. The study was
designed as a quasi-experimental study with pre-post intervention analysis. The sample included
all 25-general practitioners in the local unit of Caserta (Italy) and 877 patients under their care.
This study comprised a retrospective analysis of the patient's medical records, and a prospective
follow up of the patients after the intervention; the observational period was 36 months (18
months before and 18 months after the intervention). The sample included patients older than 18
years, receiving at least one lipid-lowering medication regardless of the prescription as primary
or secondary prevention.
The variables analyzed included drug utilization (medication adherence), clinical targets
(serum cholesterol and low-density lipoprotein (LDL) values), and process indicators (LDL
follow up, and risk factors assessment). Like in the study performed by Casula et al. (2016),
Arcoraci et al. (2014) used the MPR to measure medication adherence. The authors collected
retrospective data from the Caserta health agency's database and the longitudinal prospective
data from the practitioners' medical records. The statistical analysis was carried on by means and
standard deviation, as well as chi-square tests, considering values of p <0.05 statistically
significant.
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In the study, the intervention included a1-day intensive training focused on three main
topics: first, an educational update on clinical recommendations, secondly, clinical case
discussions, and lastly, strategies and tools to monitor medication efficacy and safety. After the
intervention, Arcoraci et al. (2014) found that the educational program did not have any
significant effect on the levels of serum cholesterol or LDL levels or in the quality of care
(process indicators). However, there was a small but significant increase in adherence given by
and improvement in the MPR indicators. The difference in outcomes with the study performed
by Casula et al. (2016) may lie in the fact that in this study, the patients were already taking
statins. That could explain that serum cholesterol, and LDL levels did not show a significant
improvement despite the increase in medication adherence.
Nevertheless, the point that providers accepted to be included in the research voluntarily
and the lack of a control group can hinder the generalizability of the results. Also, because the
educational program was partially effective, Arcoraci et al. (2014) claim that it was probably
because of lacking focus on communication skills training. The authors also emphasized the need
for a multidisciplinary approach aiming to provide tools to assess and monitor medication
adherence and lifestyle counseling.
In contrast, the quasi-experimental study conducted by Olomu et al. (2016) over 12
months in two federally qualified health centers (FQHC) in Michigan (USA) aimed to measure
the impact and feasibility of implementation of the Office-Guidelines Applied to Practice
(Office-GAP) program on medication use. The study included all providers and staff of both
centers (six doctors, three nurse practitioners, and 18 office staff) and 243 patients (older than 18
years) with the diagnosis of diabetes mellitus (DM), coronary heart disease (CHD), or both.
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Centers were randomly allocated (coin toss) in and intervention (120 patients) and control group
(123 patients).
The Office-GAP program is composed of three main elements: providers and staff
training, patient group visit, and the use of an Office-GAP checklist at the time of follow up.
During the 90 minutes of providers training, the cardiovascular secondary prevention guidelines
and improvement on communication skills were addressed. The goal was to entitle providers
with the tools to engage and empower patients on a shared decision-making process. Patients
intervention also included educational information about lifestyle changes, medication facts, and
shared decision-making strategies. During the follow-up visits, providers and patients used the
Office-GAP checklist to complete the intervention.
The variables measured were the feasibility of the intervention and the medication usage
at baseline, 3, 6, and 12 months after the intervention. Surveys completed by the patients were
the primary source of the data. Unlike the two previous studies (Arcoraci et al., 2014; Casula et
al., 2016), the patient's self-report was the assessment method used for medication adherence,
which was verified at each visit because patients should bring their medications bottles. The
quality of the data collected was assured because of the training of the research assistants and by
standardized methods of data collection, maintaining reliability higher than 98%.
The statistical analysis was performed by using t-Test and chi-square. Besides, to analyze
the overtime changes in medication usage, they used algorithms, sensitive analysis, and a logistic
regression model to control variables such as age, race, or gender. Results demonstrated a change
from baseline use of medication, and statins adherence improved at 3 and 6 months. The strength
of this study resulted from the easy to use tools provided and the teamwork approach.
Engagement and empowerment of patients have been proved influential in medication adherence
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(Olomu et al., 2016). The intervention was performed in two small centers. The lack of
meticulous randomization might prevent the generalizability of results.
Similarly, Olomu, Hart-Davidson, Luo, Kelly-Blake, & Holmes-Rovner (2016), carried
on a one-group pretest-posttest quasi-experimental study to assess the effect of the
implementation of the Office-GAP program on patient satisfaction about patient-provider
communication and the use of medication for secondary prevention of CVD according to the
ACC guidelines.
They recruited a group of patients with diagnoses of DM, CHD, or both in a designated
FQHC in Michigan, USA. All the providers and office staff on the center were included in the
study, too, for a total of two doctors, one nurse practitioner, eight staff members, and 95 patients.
The Health Literacy Care model serves as a conceptual framework to develop Office-GAP
intervention. The program was constructed on the basis that a strong provider-patient
relationship promoted safe and effective delivery of care. The program included three elements:
training targeted to providers and staff, patient group visits, and the application of the OfficeGAP checklist tool during patient and provider encounters.
Likewise, during the training, the providers and staff received a 90 min informative
session with an updated review of the current guidelines, and communication skill tools. The
latter focuses on the patient-centered model of care with the final goal of promoting patient
empowerment and engagement. The patients received shared decision support and
communication skills training. During the patient's group visits, scientific information about
secondary prevention of CHD was provided to the patients.
The Office-GAP checklist, written at a 6th-grade level, was used in the patient-providers
encounters at 3, 6, and 12 months follow up to improve share decision making and help in the
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communication process. The COMRADE survey was used to gather data about patient
satisfaction and decision confidence. Equally, to the study by Olomu et al. (2016), medication
usage and adherence were measured by patient self-report. Descriptive statistics were used to
analyze the data collected. The authors found an increase in medication use at the time of follow
up when compared to baseline. Adherence to statins was significant at 12 months following the
implementation of the program.
The main difference between both studies was the design and the assessment of patient's
satisfaction in the latter. By the implementation of the same intervention in a different setting,
the authors demonstrated that interventions targeting providers should also address patients'
preferences and education, and an improvement in patient-provider relationship to attain desired
healthcare outcomes.
In contrast, in the RCT conducted by Gulayin et al. (2019), they could not find an
improvement in serum cholesterol levels or medication adherence. In this trial, ten primary care
practices were randomly selected to participate in a study aimed to document if a program
directed to clinical providers could improve high cholesterol management. They performed a
structured intervention that encompasses a 2-day intensive provider training, three educational
follow up visits, and the use of mobile evidence-based decision support applications. The sample
included all the primary care physicians and the patients between 40-79 years old with a history
of cardiovascular disease (CVD), high risk of developing CVD, LDL values of 190 mg/dl or
higher, or diabetes type 2.
Five practices were allocated in the intervention group and received an update in CVD
assessment, risk stratification, medication monitoring, and adherence management. During the
follow-up educational visits, specialized professionals identified prescription barriers and
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provided feedback. Besides, the mobile application included evidence-based guidelines and CVD
risk estimator tools.
The objective of the study was to achieve a change in LDL levels at 12 months after the
intervention. The research also looked for an increment in patients with the proper dose of
statins. Additionally, the patient's adherence was assessed through a patient's self-report using
the Morisky-Green questionnaire. Trained, certified research nurses performed data collection.
The statistical analysis takes into consideration the cluster design to provide a 90 % statistical
power (Guyalin et al., 2019).
After the patient screening, they randomly selected 357 patients and allocated 178 in the
control group and 179 in the intervention group. After the intervention, they accounted for an
increase in the number of appropriate doses of prescribed medication in the intervention group.
However, the study failed to demonstrate a significant improvement in the serum levels of
cholesterol or patient adherence to statins by 6 and 12 months follow up. Lack of adherence was
comparable to other studies that demonstrate that statin adherence tends to decrease over time
(Rash, Campbell, Tonelli, & Campbell, 2016). Also, failure to achieve the desired outcomes
could be in part because the intervention was focused on providers following the guidelines and
enhancing prescription skills but lacked focus on communication tools and patient-centered care.
Lastly, in contrast with the rest of the studies, the RCT carried on by Lowrie, Lloyd,
McConnachie, and Morrison (2014) was based on the hypothesis that a pharmacist-led
intervention addressed to primary care providers could improve statin prescription and serum
cholesterol levels. In doing so, out of the 238 primary care practices in Glasgow (UK), 49 were
randomly requested to join the study, but only 31 practices agreed to participate. Patients
included in the study should have been diagnosed with cardiovascular disease. Baseline data was
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collected from practices patients records, completing a subset of 4,040 patients. After clustering
the practices in two separate groups considering if they were group practice or single-handed
practices, they paired them according to similar characteristics. Then, they randomly selected
one practice out of each pair for the intervention arm and the other for the control group.
The intervention included a pharmacist working at the clinical practice providing
organizational support, identifying providers' barriers for prescriptive changes, finding solutions
to overcome those barriers and to provide general practitioners scientific evidence for each
patient management. The pharmacist was also responsible for following patients to improve
medication adherence. The purpose was to measure how many patients attained normal levels of
serum cholesterol, and the relationship between those levels and the prescription of statins.
Data collection was performed by two researchers that were blinded to practices
allocation to prevent collection bias. Blinding was strictly followed to avoid performance and
detection bias. The study established that a higher number of patients in the intervention group
accomplished serum cholesterol target levels. A follow-up analysis demonstrated an increase in
prescribing practices that have persisted over the years (Lowrie et al., 2014). Lower levels of
cholesterol in the patients in the intervention group suggested an increase in medication
adherence. Furthermore, the study highlights the importance of pharmacists, healthcare
providers, and patients to achieve a positive outcome in medication management.
Risk of bias
The analysis of the risk of bias was performed following the recommendation of the
Cochrane collaboration tool to assess the risk of bias in systematic reviews that include six main
areas—selection, performance, detection, attrition, reporting, and other types of bias (Higgins et
al., 2011). The overall risk of bias among the studies was low. The sampling selection was
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carefully determined, and in some instances, the whole population was included in the studies,
allocation of subjects among the studies preclude selection bias, which allows the possibility of
generalizability of findings. The randomization process and the recollection of data were
carefully designed to prevent biases.
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Table 1
Analysis of individual studies

Articles

Purpose

Methodology
/Intervention

Sample/location

Outcomes

Results

Arcoraci et
al. (2014)

To compare CVD
prevention before
and after the
implementation of an
educational program
targeting GP.

Pre-post
intervention
Quasiexperimental
Retrospectiveprospective
analysis

25 GP,
887 patients
>18y taking
lipid-lowering
medications/
Italy

Measuring
clinical
outcomes:
target
cholesterol and
LDL levels

Partial
achievement
on
cholesterol
and
triglyceride
blood levels
which that
was not
significant.
Adherence
increased
significative
and no
difference in
the quality of
care
(process).

1-day training
program focused
on clinical
guidelines on the
use of lipidlowering
medication for the
prevention of
cardiovascular
disease (CVD).

Casula et al.
(2015)

Assess how effective
an informative and
educational program
targeting providers
could be on
improving
medication
adherence and
persistence to statin

Quasiexperimental pre
and postintervention
Two activities.
First, a scientific
document
focusses on
clinical
management of
dyslipidemia—
diagnosis,
education,
adherence, statin
use.
Secondly,
aggregated data
information with

Drugutilization:
medication
adherence
Process
indicators:
Identification
of risk factors,
proper followup

705 GP
Medication
10,621 patients
adherence and
5833
persistence
preintervention
4788
postintervention/
Italy
.

They found a
significant
increase in
adherence in
the postintervention
cohort and
an increase
in effective
prescriptions.
Clinically
and
statistically
relevant
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Gulayin et al.
(2019)

Lowrie
Lloyd,
McConnachie
& Morrison
(2014)

data about their
patient use of
statin compared
to other practices
Test if a complex
Cluster RCT
intervention aiming
Three
to providers can
components
improve treatment
intervention:
and control of
Intensive 2-day
hypercholesterolemia training based on
among patients with guidelines, CV
moderate to high
risk assessment,
CVD risk
diagnostic,
management,
monitoring and
dealing with
adherence issues
Three quarterly
educational
outreach visits:
onsite face to
face, feedback,
identification of
barriers
Mobile health
application to
facilitate EB
decisions support
To assess if a
pharmacist-led
complex intervention
delivered to primary
care providers
(doctors and nurses)
could improve
statins prescription
and attain target
cholesterol levels
beyond one year.

RCT matched
cluster design
Pharmacies
provided
organizational
support, identify
barriers and
potential
candidates for
statins, assist GP,
and NP.
overcome
barriers, identify
suitable patients
according to
guidelines.
Prepared
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10 centers
5 intervention
5 control
357 patients
179 intervention
178 control/
Argentina

The net change
in LDL levels
at 12 months,
the number of
at-risk patients
with the correct
dose of statins.
Level of
medication
adherence

No
difference in
LDL levels
at the end of
the trial
Increase in
better
prescription
patterns.
No
significant
difference in
patients with
high
adherence to
statins after 6
and 12
months
follow up.

30 practices, and
4040 patients
(15 singles,
16 group
practice)
15 practice
2373 patients,
37 GP, 20
nurses in the
intervention
group
15 practices,
3352 patients,
35 GP,18 NP in
the control
group

Achieve
cholesterol
targets and
proper follow
up

The
intervention
group had a
higher
proportion of
patient with
target levels
of
cholesterol
and
improvement
in
prescription
patterns

EDUCATIONAL PROGRAM AND MEDICATION ADHERENCE

Olomu, HartDavidson,
Luo, KellyBlake &
HolmesRovner
(2016)

Olomu et al.
(2016)

individualized
written EB
recommendations,
educational
support, and faceface training,
feedback, and
cost-effectiveness
to GP and nurses
Evaluate the
Pretest-posttest
feasibility of
Quasiimplementing the
experimental
Office-GAP program Physicians and
and its impact on
staff training (90
patients and
min) in the
physician
secondary
satisfaction with
prevention of
communication and
CHD and
decision making, and communication
the use of guideline
skills.
medication for CHD Patient group
prevention
visits.
Use of OfficeGAP checklist
tool at follow up
Determine the
feasibility of
implementation of
the Office-GAP
program and its
impact on the
implementation of
current guidelines for
CHD prevention as
well as prediction of
medication use
(adherence and
persistence)

Quasiexperimental
Physicians and
staff training (90
min) in the
secondary
prevention of
CHD and
communication
skills.
Patient group
visits.
Use of OfficeGAP checklist
tool at follow up
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2 doctors,
1 NP, 8 staff
members, and
95 patients/
Ingham County,
Michigan,
USA

The feasibility
of model
implementation
measured by:

6 MD,
3 NP,
18 staff, 243
patients/
Michigan,
USA

Feasibility of
model
implementation
Drug
utilization
measured by
improvement
in prescriptions
and patient
self-report
adherence at
each visit

Efficacy of the
program
measured by
the patient's
satisfaction
(COMRADE
survey)
Medication use
and adherence
by self-report

Significant
increase in
the drug
utilization
and
adherence to
statins at 6
and 12
months

Increase the
use of
medication
in the
intervention
group,
adherence to
statin
improved by
3 and 6
months
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Discussion
Summary of the Evidence
Medication nonadherence is a very prevalent healthcare issue. Health care professional
intervention can be beneficial to achieve patient's adherence to statins as well as for maintaining
healthy levels of cholesterol and improvement in lifestyle. General practitioners are in an
advantageous position to deliver the necessary education to increase patient adherence and
consequently improve healthcare outcomes (Oñatibia‐Astibia et al., 2019). The overall evidence
gathered in this review shows the importance of educational and informative intervention
targeting providers over lipid-lowering medication adherence. In the databases examined, there
was not a previous systematic review that addresses the effect of such interventions.
In the six studies appraised, the tools to assess medication adherence varies. Two studies
used the medication possession ratio (MPR) (Arcoraci et al.,2014; Casula et al.,2016). This
method to determine adherence relies on the dispensing records provided by the pharmacy
databases, and it is calculated by dividing the days covered by a drug by the days in the
observation period. Ratios over 80 % are considered ideal (Arcoraci et al.,2014; Casula et
al.,2016). This method's limitation depends on the fact that there is no guarantee that the patients
are taking the medication as prescribed; but that they are receiving the refills on time. One study
(Gulayin et al., 2019) used the Morisky-Green questionnaire to assess medication adherence. The
Morisky-Green questionnaire, also known as MMAS-8, is an easy to use, cost-effective validated
tool to evaluate medication adherence; however, it should be used with other methods of
validation due to consistency issues regarding overestimation of patients' responses (Sison,
2018). Two other studies (Olomu et al., 2016; Olomu, Hart-Davidson, Luo, Kelly-Blake, &
Holmes-Rovner, 2016) measured adherence by patient's self-report and by checking the pills
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bottles for validation. Counting the pills left in the containers prevented the effect of patients
overreporting. In contrast, Lowrie et al. (2014) did not measure adherence as a variable, yet,
they assessed serum cholesterol levels as an indirect indicator of adherence. These results are
like a systematic review that found that in 98 % of the studies, there was not a consistent method
to measure medication adherence or persistence (Deshpande et al., 2017).
Simplification of the medication regimen and better communication between patients and
providers can be promising to achieve better outcomes. Based on that premise, Casula et al.
(2016) implemented an informational, educational intervention directed to providers to increase
adherence to lipid-lowering medication. In this pre-post intervention quasi-experimental study,
they compared the patient's adherence to lipid-lowering medication between two cohorts (pre and
post-intervention cohorts), and they found a significant increase in patient's adherence to statins.
In this study, the intervention intended to increase providers' awareness of updated clinical
guidelines and benchmark their data with other providers in the area. That simple intervention
produced a change in the provider's attitude toward patients, leading to an increase in adherence
by the end of the trial. A change in practitioners' attitudes has a positive influence on patients'
behavior because when prescribers are involved, that means improving the prescriptive activity
at the source and more patient education and monitoring.
However, the study has some limitations. First, the lack of a control group does not
allow to compare the effect of the intervention against the usual care to make more reliable
conclusions. Secondly, they did not consider other comorbidities or any additional medications.
The patients included in the study were first-time statin users, making it difficult to measure the
impact of different factors over the attained results.
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Meanwhile, Arcoraci et al. (2014) implemented an educational program directed to
general practitioners with the objective to measured quality of care by increased patient
adherence to lipid-lowering drugs, decrease serum levels of cholesterol, and identification and
monitoring of other risk factors for cardiovascular events. The intervention consisted of a 1-day
training with actualization on clinical guidelines and the analysis of tools and strategies to
monitor the lipid-lowering medication efficacy and adherence. By the end of the study, there was
an increase in adherence, given by higher MPR values. Though, the authors considered the study
partially successful regarding the effect on serum cholesterol and LDL level. This study was
performed in patients that were already on statins, and it is probably that they already were on
the target level or that the degree of improvement would not be so significant. Besides, the
intervention only focuses on providers' training, lacked focus on improving communication
skills, and did not offer the tools to monitor and empower patients to be more adherent. That
could be the reason why the intervention was just partially effective. Anyhow, the characteristics
of the sample considered in this study and the way the educational program was structure could
make generalizability of the results questionable.
The studies performed by Olomu et al. (2016) and Olomu, Hart-Davidson, Luo, KellyBlake, and Holmes-Rovner (2016) have similar interventions and objectives. The intervention
took place in two different settings, with two different sample populations. The interventions
carried on in these two studies were more structured than the interventions performed in other
studies (Casula et al., 2016; Arcoraci et al. 2014). The study was designed around the application
of the Office-GAP (guidelines applied to practice) program. The framework for these two studies
was based on the patient-centered care model. Moreover, it included the empowerment and
engagement of patients in the decision-making process.
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In the study by Olomu et al. (2016), the two practices chosen were randomly assigned
either to the intervention or control group. The intervention included a 90-minutes of training to
providers and staff, offering an update on the clinical guidelines for secondary prevention of
cardiovascular disease in consonance with the recommendations of the American Heart
Association (AHA). Patients were also educated on decision-making, the establishment of goals,
and scientific data about diabetes mellitus (DM) and coronary heart disease (CHD). The followup visits included the application of the Office -GAP checklist. It is an easy to use instrument
that allows patients and providers to review treatment options and patients' preferences. The
overall adherence to statins and other medication for cardiovascular prevention increased in the
intervention group. Statin use increased at 3 and 6 months related to an improvement in
providers' prescriptions after the intervention. However, at 12-months, the percentage of
adherence was not statistically significant. This behavior correlates with previous studies that
demonstrate the decrease in adherence over time (Rash, Campbell, Tonelli, & Campbell, 2016).
According to Olomu et al. (2016), the strength of this study relies on teamwork, the ability to
engage patients, and the usefulness of the checklist as a reminder of proper follow-up. However,
sample size and the characteristics of the site makes generalizability of results uncertain.
Nevertheless, this study highlights the importance of patient engagement and the need to
establish a partnership between patients and providers to attain the desired healthcare outcomes.
Similarly, the study performed by Olomu, Hart-Davidson, Luo, Kelly-Blake, and
Holmes-Rovner (2016) was based on the premise that when patients are involved in the
management of their chronic conditions, they are more proactive and attain better healthcare
outcomes. They implemented a shared decision-making intervention that included
communication skill training for both patients and providers. Their primary focus was to create a
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stable patient-provider relationship. The providers' intervention included a discussion of
prevention guidelines and communication skills. The latter was based on the Patient-Centered
Care Method of Communication, aiming to enhance patient engagement and empowerment.
The intervention produced an increase in the number of patients using statins and other
medication for secondary prevention of CHD (Olomu, Hart-Davidson, Luo, Kelly-Blake, &
Holmes-Rovner, 2016). Statins adherence increased by 6 and 12 months with a probability of
adherence of 52 % at 6-months and 34% at 12-months. The overall results of this study
demonstrated that the use of a simple checklist, such as the Office-GAP, enables providers to
thoroughly contemplate the use of evidence-based tools to deliver a higher quality of care. The
authors explained that the improvement in medication adherence could be the result of better
patient-provider relationships and communication and enhanced prescribing practices. Despite
the strength of the study, the design lacking control group and randomization, as well as the
small sample, prevent generalization of the results. Additional research should be conducted to
validate the effect of such intervention in the improvement of statin adherence and the
consequent prevention of cardiovascular events.
Similarly, the pharmacist-led intervention conducted in the RCT by Lowrie et al. (2014)
achieved an improvement in the appropriate prescriptions of statins, and the consequent decrease
in LDL and serum cholesterol at the 12 months follow up, suggesting an increase in adherence.
This study included a pharmacist collaborating, educating providers, assessing for barriers to
implementation, detecting the patients needing therapeutic changes. The effect of adding a
pharmacist to the healthcare team positively impact the patient's adherence because pharmacist
can produce more follow up, patients' education, and practitioners counseling. However, even
when adding a pharmacist to the project would be ideal for decreasing nonadherence, it is not
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always a viable and cost-effective solution due to the differences in the economic and structural
organization of the healthcare system in any given setting.
Unlike the other studies appraised, the RCT performed by Guyalin et al. (2019) did not
demonstrate an improvement in lipid-lowering medication adherence. In this RCT, the sample
was composed of the practitioners of ten centers in different locations in Argentina. Patients
included in the study were 40-74 years old, who have at least one of the following inclusion
criteria: DM, high cardiovascular disease (CVD) risks, an established CVD, or LDL levels above
190 mg/dl. The authors used a three-component intervention and evaluated the effect of such
intervention on the control of hypercholesterolemia in patients at risk.
The intervention included a 2-day training followed by three educational visits and the
use of a mobile evidence-based decision-making application. The training included guidelines
updates, information on risk assessment tools, management, and monitoring of hyperlipidemia
and adherence topics. Meanwhile, in the quarterly visits, the practitioners received feedback and
help to identify possible barriers. Other additional support tools were provided to the intervention
group, such as weekly text messages and training to pharmacist assistants on patient counseling
and adherence.
The intervention proved significant to reduce cardiovascular risks after the first six
months; however, this change did not continue at 12 months. Also, the percentage of patients
receiving the appropriate dose of statin increased, yet no difference between the two groups was
identified regarding adherence. These results are like other studies that demonstrate a decrease in
adherence rates over time (Deshpande et al., 2017). It is possible that the type of intervention
strongly focused on scientific data was not enough to achieve the desired outcomes, mainly
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because of the lack of patient involvement or the lack of training in better communication
pathways.
Different interventions have been tried to increase medication adherence with mixed
results. In a systematic review conducted by Rash, Campbell, Tonelli, and Campbell (2016),
including 25 randomized control trials (RCT), they found that a well-structured education-based
intervention had a significant impact on statin adherence. However, not all the education trials
were successful. Only those studies that depicted vigorous risk factor counseling sessions,
lifestyle modification, and visual representation of coronary atherosclerosis improved the
proportion of adherence. Furthermore, when a multifaceted intervention was used—education,
pharmacist follow up, counseling, behavioral intervention, and medication reminders—there was
improved adherence. In this systematic review, simplification of medication—using a polypill—
was by far the best intervention leading to better adherence.
Patients' education and close patient monitoring interventions have been tried to increase
the patient's adherence. It is a fact of the role that providers play in modeling patients' behavior
through a strong patient-provider relationship, proper communication, and close monitoring
(Brinton, 2018). Overall, providers recognized that excellent communication, patient-centered
care, and patient education are crucial to achieving long term adherence; however, in some
instances, they avoid discussing those issues, omit the use of statins in primary prevention, or do
not involve patients in the decision-making process (Kruger et al., 2018)
Limitations
This review has some limitations. First, only two of the included studies are RCT. It is
known that RCTs are considered the most reliable source of evidence (Mastrian & McGonigle,
2017) and usually is the best approach to demonstrate causality (Holly, 2014). Secondly, the
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heterogenicity of the interventions and the different designs decrease the likelihood of
generalizability of the results. Furthermore, the small samples, lack of control group, or
randomization hinders the reliability and strength of the findings. Lastly, this review focused on
intervention to primary providers or general practitioners and did not focus on the role that
pharmacists play in the education, monitoring, and follow up to decrease nonadherence among
patients at risk.
Studies included have their specific limitations. For instance, some of the interventions
only included scientific updates to providers (Arcoraci et al.,2014; Casula et al.,2016; Guyalin et
al., 2019), which proved only partially advantageous in part because of a lack of patient
involvement. In two studies, the intervention also included patients as recipients of decisionmaking skills and communication techniques (Olomu, Hart-Davidson, Luo, Kelly-Blake, &
Holmes-Rovner, 2016; Olomu et al., 2016). However, the small samples and the specific
characteristic of the setting limits the generalizability of the results precluding the need for
further studies.
Besides, most of the studies focused on statins used for secondary prevention (Guyalin et
al., 2019; Lowrie at al., 2014; Olomu, Hart-Davidson, Luo, Kelly-Blake, & Holmes-Rovner,
2016; Olomu et al., 2016) and the other two included the patients regardless of the purpose of
statin prescriptions (Arcoraci et al.,2014; Casula et al.,2016). Therefore, it is challenging to link
adherence with the intention of primary or secondary prevention based on these findings.
Besides, the lack of a standard tool to measure patient adherence hinders the ability of providers
to address and monitor nonadherence adequately. Furthermore, only in one of the studies, the
effect of the intervention has been considered in the long term, making it harder to analyze the
impact of such interventions in the adherence-persistence process.

EDUCATIONAL PROGRAM AND MEDICATION ADHERENCE

36

However, the review also has some strengths. First, there is no other review in the
databases screened that addresses the effect of an educational intervention to providers on
patient's medication adherence. Secondly, it highlighted the critical role that providers play in
attaining a higher level of adherence. Finally, it emphasized the importance of educating
providers and improving patient-provider communication as the right approach to address
nonadherence.
Conclusions
Six studies were included in the review: two RCT and four quasi-experimental studies. In
all the studies, there was an educational intervention targeting providers to increase lipidlowering medication adherence, reduction of serum cholesterol levels and risk of CHD, and
improvement in the provider's ability to prescribe and follow guidelines to manage patients with
dyslipidemias. The structure of the educational program was diverse but mostly focused on
scientific updates and feedback. In two of the studies, patients were also educated on decision
making and communication strategies (Olomu, Hart-Davidson, Luo, Kelly-Blake, & HolmesRovner, 2016; Olomu et al., 2016).
The population studied mostly included patients on secondary prevention of CHD.
However, two of the studies included all the patients with statins prescription without regard to
whether they were for primary or secondary prevention (Arcoraci et al., 2014; Casula et al.,
2016). Additionally, there was not a standard tool to assess medication adherence across the
studies. Nevertheless, five out of the six studies found a significant increase in medication
adherence after the intervention (Arcoraci et al., 2014; Casula et al., 2016; Lowrie, Lloyd,
McConnachie, & Morrison, 2014; Olomu, Hart-Davidson, Luo, Kelly-Blake, & Holmes-Rovner,
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2016; Olomu et al., 2016). Overall in the six studies, the authors found enhanced providers'
performance abiding by the AHA guidelines.
It is feasible to increase medication adherence on the patient with dyslipidemia through
interventions addressing providers; however, patients should be engaged in the decision-making
process. Interventions should include not only scientific updates but also communication skills
and tools to engage, empower patients in a patient-centered model of care. When patients and
providers are equally involved in the process of care, it is possible to achieve better healthcare
outcomes. More research is needed to prove the efficacy of intervention targeting providers over
medication adherence in other chronic conditions and different settings to establish
generalizability of findings.
Quality improvement project
Patients' adherence to lipid-lowering medication is often related to different factors.
Patients' beliefs and health literacy, providers' attitudes, patient-centered care, and simplification
of medical regimen have been invoked among the principal factors that facilitate adherence
behavior (Rash, Campbell, Tonelli, & Campbell, 2016). Prescription patterns have been used
lately as a measure of the quality of care; therefore, medication adherence and its relationship
with positive health outcomes have been linked with a better quality of care (Seabury,
Dougherty, & Sullivan, 2019).
The finding of the systematic review showed that it is feasible to improve patient
adherence through a process of education and engagement of primary care providers. A change
in the attitude of general practitioners with more emphasis on providing patients with the
appropriate information lead to an increase in adherence and persistence. Besides, better
prescribing practices and more providers' expertise enhance patients' trust and consequently
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promote a change in patients' attitudes and better adherence (Casula et al., 2016). Primary care
providers are in an advantageous position to influence patients' attitudes and increase adherence
to lipid-lowering medication, which will contribute to decreasing the mortality due to
cardiovascular disease.
Primary Aim
Therefore, the primary aim of this quality improvement (QI) project was to increase
patient adherence to lipid-lowering medication through a structured educational intervention in a
local primary care center. The QI project aimed to provide an educational intervention to
healthcare staff to increase awareness and assessment skills on lipid-lowering medication
adherence. Besides, it was also expected to improve healthcare providers' communication and
patient education skills to increase the patient's adherence to lipid-lowering medication.
Goals and outcomes
The goals of the educational intervention addressed three crucial areas related to and
associated with the patient's adherence to lipid-lowering medication. In this regard, the proposed
educational program would promote the healthcare team's involvement in the identification of
patients who will benefit from lipid-lowering medication, promoting patient's engagement in the
decision-making process, and addressing lipid-lowering medication adherence.
The short-term goals included promoting the healthcare team's involvement in the
identification of patients who will benefit from lipid-lowering medication (guidelines), promote
patient's engagement in the decision-making process (education), and assess and educate on
medication adherence (adherence). Additionally, the long term goals of the QI project included
the introduction of a systematic assessment and education on patients with hypercholesterolemia
that will reduce the incidence of adverse cardiovascular events and an improvement in the

EDUCATIONAL PROGRAM AND MEDICATION ADHERENCE

39

healthcare indicators. The QI project outcomes included an improvement in the center healthcare
team skills to manage patient's nonadherence to lipid-lowering medications. Those skills would
empower the team to provide patient education in a patient-centered care environment
Rationale
Patient's nonadherence to medication usually hinders the role of lipid management for
primary and secondary prevention of cardiovascular disease (CVD). Several factors play an
essential role in patient's nonadherence, such as ineffective communication between provider and
patient, insufficient education, improper follow-up, and perceived need from a patient
perspective (Casula et al., 2015). Although the importance that lipid-lowering medications play
in the prevention of CVD, there is a lack of consensus about how to address patient's lack of
adherence in the long term in primary care, and there is no standardized method to measure and
address adherence (Van Driel et al., 2016).
Interventions should be tailored according to the population's characteristics. For
instance, suggested strategies approach nonadherence by emphasizing educational and
behavioral approaches. Others provide recommendations to improve patient-provider
communication, not only addressing the patient's beliefs but also the providers' attitudes (Ruppar
et al., 2015). Thus, it is essential to implement interventions involving providers in devising
strategies to improve patient's perception about the benefit of adherent behaviors to reduce the
risk of adverse CVD events. Therefore, considering the critical role of providers and staff in
modeling patients' beliefs and perceptions, it is essential to increase their understanding of how
to address nonadherent patients.
Medication nonadherence is considered a significant public health problem because it
leads to reduced healthcare outcomes with a consequent increase in healthcare costs. In the
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United States, about $100 billion are disbursed to services that are related to poor medication
adherence (Kini & Ho, 2018). More than $300 billion of unnecessary healthcare expenses—10%
of healthcare budget—are the consequence of nonadherence (NEJM Catalyst, 2019). Therefore,
interventions to increase medication adherence could have a beneficial effect on population
health more significant than any specific treatment.
Evidence shows that it is feasible to increase lipid-lowering medication adherence
through a comprehensive educational intervention. Based on the evidence gathered, this quality
improvement project was implemented to increase healthcare team awareness of the need to
assess and monitor for patient's adherence to lipid-lowering medication, to promote and reinforce
patient education and patient engagement on the decision-making process.
Quality Improvement Method
The QI project took place in a Primary Care Center, which is composed of two physical
facilities. All members of the staff were invited to participate in the QI project. The proposal was
submitted to the Institutional Review Board (IRB) of Florida International University for
approval. Once approved, the DNP student in agreement with the office manager established a
date for the implementation of the project.
The program was designed as a pretest-posttest intervention. It encompassed three main
components. Firstly, an initial assessment of staff and providers' knowledge regarding guidelines
for lipid-lowering medication, medication adherence, and patient education was performed by
the application of a pre-intervention questionnaire. Secondly, the educational program was
carried on. Lastly, the post-intervention questionnaire was given to all the participants. All data
collection, data analysis, and storing were performed at the clinical site. The pretest and posttest
data were recorded in excel. Both surveys were scored individually and as a group with a
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percentage. Results from pre- and post-intervention questionnaires were compared for
improvement in group score.
Program Structure and Outline
The program included a pretest survey. The survey was composed of twenty questions
that addressed the main objectives of the QI project. Answers from this survey provided any gap
of knowledge and the degree of understanding about the primary topics addressed in the QI
project. The questions assessed knowledge about lipid management latest guidelines, the ability
to assess for medication adherence, and the readiness to provide patients education.
The educational program was structured in a way that responded to the three main topics
of the QI project (guidelines, adherence, and education). The educational intervention was
carried on in a face to face program that lasted 60 minutes and focused on the latest guidelines
published by the American Heart Association (AHA) to manage hypercholesterolemia for
primary and secondary prevention, medication adherence, and patient education. Additional
resources on how to promote patient engagement through patient education were also provided.
Two different sessions were offered, one in each physical facility, to accommodate the
staff according to their location and schedule, and to keep social distancing. The program was
designed as an interactive activity, including a PowerPoint Presentation (PPP) and distribution of
informative handouts. Emphasis on patient education and empowerment was a priority. The final
step was a follow-up post-intervention survey.
Both pre- and post-intervention questionnaires were anonymous to protect participants'
privacy. They were scored individually with a percentage, and then the group average was
calculated. Then, results were compared for any improvement in group scores. The DNP student
was responsible for applying both the pretest and posttest and the data collection and analysis.
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Evaluation
The completion of the post-intervention questionnaire accomplished the evaluation of the
QI project. The short-term impact of the educational program was evaluated by their responses in
the post-intervention test, expecting an improvement in the skills to assess, monitor, and educate
patients regarding lipid-lowering medication adherence. The long-term impact of the program
should be accomplished and monitored afterward by the Center's management. The
implementation of a systematic process to assess and monitor patients for lipid-lowering
medication adherence and patients' feedback will provide structure to the delivery of healthcare.
Plan for sustaining change
Periodic evaluation of the QI project impact should continue to guarantee long-term
goals. Education reinforcement, creation of a checklist that addresses the three crucial objectives
of the QI project will be carried on in the Center to assure the sustainability of changes
Results
The QI project population included eight members of the staff who are involved directly
with patient care. Demographic characteristics are included in Table 2. The staff was composed
of 4(50%) medical assistants and 4(50%) patient care coordinators. All were the Hispanic
(100%), mostly female (7= 87.5%), and over 40 years old (5= 62.5%).
Overall, there was an improvement in the individual scores when pretest and posttest
results were compared (Figures 1-3). As a group, there was a 24 % improvement after the
intervention. It was also found a 30 % improvement in guidelines knowledge, 29% in medication
adherence knowledge, and 14 % in patient education, as shown in Table 3.
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Pretest analysis
Guidelines knowledge
While 75 % of the respondents believed they are familiarized with the latest guidelines
for cholesterol management, only 25% could identify the patient who would be a perfect
candidate for lipid-lowering medication for primary prevention. Additionally, only 50%
identified the patients at high risk or recognized the target LDL levels on high-risk patients.
Regarding risk identification, only 50 percent of the participants recognized that diabetes
mellitus and smoking are considered significant risks for cardiovascular events. Meanwhile,
87.5 % identified HTN as a risk factor too.
Medication adherence knowledge
Only 50% of the respondents are familiarized with the concept of medication adherence.
While 87.5 % consider it is essential to assess medication adherence in every encounter, they do
not use a standardized assessment tool. Out of the total, 62.5 % consider that the best method to
assess for adherence is to measure serum cholesterol and LDL level regularly. Lack of
knowledge about the consequence of nonadherence was considered the most important reason
why patients fail to take the lipid-lowering medication as prescribed, followed by impaired
memory and forgetfulness with 62.5%.
Patient education
Regarding patient education, 62.5% states that they always provide patient's education
about cholesterol management, 50 % educate patients about medication adherence, and 50 %
often involve patients in the process of decision making. Besides, 75 % considered that patients
should have an active role and should be included in creating the treatment plan, as well as be
provided with the necessary skills. They all agree that discussing lifestyle and medication side
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effects should be included in the education plan. However, only 50 % consider that assessing for
medication adherence in every encounter will be a beneficial intervention to increase adherence
among the patients, and 62.5% will include the use of technology (automatic reminders) and
interactive educational activities to improve adherence.
Posttest analysis
Guidelines knowledge
After the educational intervention, 87 % of the subjects were able to identify the perfect
candidate for lipid-lowering medication, and 62.5% were able to recognize the target LDL levels
on high-risk patients. Regarding risk factors, all the participants (100%) recognized hypertension
and smoking as significant risk factors, meanwhile 87.5 % identified DM as a risk factor too.
Medication adherence knowledge
All participants (100%) considered essential to assess for medication adherence in every
encounter, and 87.5% could adequately define the concept of medication adherence. Out of the
total, 87.5 % considered that measuring the serum cholesterol and LDL levels are the best
method to assess for patient's adherence. Side effects of the lipid-lowering medication were
considered by 75 % of the respondent as the main reason for patients' nonadherence.
Patient education
All the respondents agree that education should be provided in every encounter and that
patients should play an essential role in the decision process. The 100 % agree that education
should include changes in lifestyle, medication adherence, and side effects. They also agree that
assessing adherence in every encounter and the use of some sort of technology could help to
improve patient's adherence to lipid-lowering medication.
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Discussion
Although the systematic review addressed interventions targeting mainly primary care
providers, this QI project included mainly the ancillary staff that is directly related to patients.
The supporting staff is in a perfect position to reinforce education, assist with medication
adherence assessment, and engage patients. Healthcare delivery is a complex process, which is
carried on by members of a multidisciplinary team. The quality and safety of that process are
closely related to the characteristic of teamwork (Rosen et al., 2018). Teamwork can be helpful
not only to identify barriers and modify patient behavior (Olomu et al., 2016)., but also to
improve patient education and engagement. The implementation of the QI project improved the
staff skills and knowledge to carry on a more inclusive role in the patient's care.
Assessment for lipid-lowering medication, monitoring for adherence, and educating
patients should be included in every encounter and followed up. Advanced practice nurses at the
forefront of the healthcare team in primary care are in a position to influence team perspective
and awareness. Their role in the assessment, education, and engagement of patients also entitles
educating and empowering the healthcare team.
Conclusions
It is feasible to increase lipid-lowering medication adherence for primary and secondary
prevention by targeting providers and staff. Increasing staff knowledge and skills increase the
likelihood of better quality of care, providing comprehensive support to providers in the patient's
care. Improving assessment tools, increasing patient engagement, and broadening patient
education can be achieved with a team effort. More research is needed to assess the effectiveness
of such interventions in the patient's adherence.
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Table 2
Demographic
Gender

Number (n=8)

Percentage

Male

1

12.5 %

Female

7

87.5 %

Number (n=8)

Percentage

Under 40

3

37.5 %

Over 40

5

62.5 %

Ethnicity

Number (n=8)

Percentage

Hispanic

8

100 %

Position

Number (n=8)

Percentage

Medical Assistant

4

50 %

Patient care coordinator

4

50 %

Age
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Table 3
Group scores: Pretest/posttest analysis
Average scores

Pretest

Posttest

Improvement

Guidelines
knowledge

48%

78%

30%

Medication
adherence

51%

80%

29%

Patient education

78%

92%

14%

Group average

48%

72%

24%
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Figure 2
Guideline knowledge individual scores
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Figure 3
Medication adherence individual scores
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Figure 4
Patient education individual scores
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Appendix A: Dissemination plan
Cardiovascular disease (CVD) continues as a leading cause of death in the United States
(Kochanek, Murphy, Xu, & Arias, 2019). Statins and other lipid-lowering medications have
been proven effective in reducing the risk of cardiovascular events. However, it is estimated that
half of the patients prescribed statins cease their use within their initial year of treatment, and it
continues falling in the subsequent years (Rash, Campbell, Tonelli, & Campbell, 2016).
Medication adherence is a complex process that involves elements from both the patients
and the providers (Kini & Ho, 2018). Different factors lead to patient nonadherence. However,
there is no consensus on how to measure and address nonadherence in primary care (Van Driel et
al., 2016). Instead, medication adherence has been linked to the quality of care (Seabury,
Dougherty, & Sullivan, 2019). Hence, primary care providers are in an advantageous position for
modeling patients' behavior through a strong patient-provider relationship, proper
communication, and close monitoring (Brinton, 2018).
Several initiatives have been proposed to increase patient adherence. For instance,
improvement of patient/provider relationship, follow up guidelines, generating clinical pathways
to guarantee appropriate decision-making, strengthening of healthcare delivery, adequate followup, simplification of medical regimen, and the use of technology have been proposed (Lee et al.,
2016).
The findings of the systematic review demonstrated that it is feasible to increase patient
adherence by increasing providers' awareness and engagement. Those results led to the proposal
of a quality improvement project (QI) in the primary care setting. All the studies reviewed have
in common the lack of a standard method to assess medication adherence. However, all of them
apply different types of educational interventions targeting providers to increase medication
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adherence. Interventions were dissimilar in structure, but conceptually they focus on increasing
provider's knowledge about current guidelines, improving communication skills, and
implementing a better follow up.
The QI implemented in the primary care office targeted the ancillary staff. Each member
of the healthcare team plays an essential role in the delivery of care. The intervention targeted
the gap of knowledge regarding clinical guidelines, medication adherence assessment, and
patient education. The QI shows how providing education to the staff will empower them to
reinforce patient education and could help develop new clinical pathways that include
medication assessment tools, patient education, and patients' follow up.
The findings of the systematic review and results of the QI project will be sent for
consideration to be presented in the conference of the American Association of Nurse
Practitioners (AANP) in 2021. The Journal for Nurse Practitioner (JNP) is a peer-review
publication of the AANP. The abstract will also be sent for consideration to the JNP for
publication.
At the clinical setting level, the impact of the QI will continue to be measured through
patient adherence. Serum levels of cholesterol, low-density lipoproteins (LDL), and triglycerides
(TG) will serve as an indicator of adherence. It is expected that pharmacies and insurance reports
regarding patient nonadherence drop in the next six months.
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Abstract for publication in The Journal for Nurse Practitioners
Medication adherence has been defined as the process by which patients take the medications on
how they are prescribed (Ruppar et al., 2015). Medication nonadherence has become a critical
healthcare issue. Several interventions have been tried to increase adherence. Therefore, the
objective of this review is to assess if a structured educational program directed to providers and
staff could increase medication adherence among patients who are prescribed lipid-lowering
medications for primary and secondary prevention of cardiovascular disease. The gathered
evidence will lead to the development of a quality improvement project. Three databases were
screened to answer the clinical question, and six articles were included in the review. The
educational programs ranged from 90 minutes of training up to 2-day educational sessions. The
programs included scientific updates, clinical guidelines, feedback, and communication skills.
Five out of the six studies found a significant increase in medication adherence after the
intervention. Even when different approaches were used, it is feasible to create an educational
program targeting providers and their staff to increase lipid-lowering medication adherence.
A Quality Improvement (QI) project was implemented in a local Primary Care practice. The
project was designed as a pre-post intervention survey. The purpose of the QI was to increase the
skills and awareness of the provider's staff to increase the patient's adherence to lipid-lowering
medication. After the educational intervention, there was an improvement in staff knowledge,
awareness, and skills to assess, educate, and engage patients to promote patients' adherence to
lipid-lowering medication. More research is needed to prove the efficacy of different types of
intervention targeting providers over medication adherence in other chronic conditions.
Keywords: medication adherence, lipid-lowering medication, providers, educational
intervention
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Appendix B

PRETEST-POSTTEST
Use of a structured educational program on providers to improve patient's
adherence to lipid-lowering medications.
Introduction:
This questionnaire is an essential part of a quality improvement project aiming to
increase patient's adherence to lipid-lowering medication through an educational program
targeting providers and staff.
Please, answer to the best of your knowledge. Your response will help to understand gaps
in knowledge and rooms for improvement. The questions are structured to assess your
understanding regarding cholesterol management, guidelines, assessment of patient's adherence
to medication, patient's education, and management.
Demographic:
Gender: Female ________

Male _________

Age: ____________
Ethnicity:____________________________________________
Position:_____________________________________________

Questionnaire:
Assessment of guidelines knowledge
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1. Have you received any type of training in cholesterol management for primary and
secondary prevention of cardiovascular disease?
______none

_____not sure

____yes

If yes, how many? _______
2. Please respond to the following statements:
Statement

Strongly
agree

Agree Undecided Disagree Strongly
disagree

I am very familiarized with the latest
guidelines for high cholesterol
management

I am knowledgeable about the ASCVD
(atherosclerotic cardiovascular disease)
risk calculator tools

I assess for lipid-lowering medication
adherence in every encounter

I usually provide education about
cholesterol management and
medication adherence

3. Which of these patients is a good candidate for the use of lipid-lowering medication for
primary prevention?
______ a 25 years old woman with LDL 145 mg/dl
______a 45 years old male with LDL 195 mg/dl
______an obese patient 35 years old with a family history of HTN
______an 80-year-old female with controlled HTN and LDL levels of 105 mg/dl
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4. Which of the following individuals with elevated cholesterol are considered high-risk?
Select all that apply
___ A patient with clinical ASCVD
____ Patient with LDL of 130 mg/dl
____ Age 40+ with diabetes mellitus
____ 80-year old has had a myocardial infarction
5. In patients with a history of ASCVD, the management should include:
_____ Use of high-intensity statins
_____rest as much as possible
_____use of low intensity statins
_____take omega 3
6. Which is the target value of LDL in patients at high risk of ASCVD
_____100 mg/dl
_____<70 mg /dl
_____70-100 mg/dl
_____120 mg/dl
7. Using the ASCVD risk calculator will help to:
_____identify patients at risk
_____counsel patients
_____assess for adherence to medication
_____provide the risk of patients to have a cardiovascular event in the next 10 years
8. Which risk factors, besides the levels of cholesterol, are considered to calculate the risk
of ASCVD? Select all that apply
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_____diabetes Mellitus
_____uncontrolled hypertension
_____Smoking
______diet and exercise
______weight
Medication adherence knowledge
9. In your opinion, what could be considered medication adherence?
____when patients take their medication as prescribed less than 80 % of the times
____when patient take the medication as prescribed at least 80 % of the times
____When patients forget to take their medication often.
____when patients fail to take their medication
10. Do you use any standardized tool to assess medication adherence?
_____yes

____not sure

______no

11. Do you consider it important to assess medication adherence in every visit?
____yes

_____not sure

_____not at all

12. In your opinion, which would be the best method to assess adherence?
______patient self-report

______pill counting(pt. brings bottle to the office)

______Pharmacy statements

______serum cholesterol and LDL values

13. In your opinion, why are patient’s nonadherence to lipid-lowering medication? Select all
that apply.
___lack of knowledge about unintended consequences
___Perceived believe of unnecessary treatment
___Memory impairment, forget
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___Mistrust on providers decision
___drug prices, lack insurance
___side effects
14. Which of the following is considered a consequence of nonadherence to lipid-lowering
medications?
___decrease in hospitalizations and healthcare costs
___increase in side effect
___Harm to patient's health
___There is no consequence

Patient education
15. How often do you provide education about cholesterol management and healthcare
consequences?
_____always

_____frequently

_____rarely

_____never

16. How often do you provide education about the need to be adherence to statins?
_____always

_____frequently

_____rarely

_____never

17. How often do you involve patients in the process of decision making?
____always

____frequently

____rarely

____never

18. Please, answer the following statements
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Statement

Strongly
agree

Agree Undecided Disagree Strongly
disagree

Patients should have an active role in
creating the treatment plan

Patients should be included in the
decision making
Patients should be provided with
decision-making skills

Patients should be reminded to be
adherence and to follow up

19. Patient education should include: Select all that apply
_______discussing lifestyle
_______Medication side effects
______follow up and adherence
______medication prices
20. Which interventions can help patients to be more adherence? Select all that apply
_______assessing for adherence in every encounter
______ provide automated reminders (use of technology)
______provide interactive educational activities
______provide polypharmacy
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